Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion

@Cancer_talks Check for acquired BRAF and add trametinib to overcome resistance if positive. https://t.co/75m5lWdgJw

Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line #Osimertinib Treatment in #NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion https://t.co/pzloRzs3sZ https://t.co/wo1VqocQt0